Zura Bio Ltd (ZURA) concluded trading on Thursday at a closing price of $1.96, with 7.74 million shares of worth about $15.17 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 0.51% during that period and on July 17, 2025 the price saw a gain of about 51.94%. Currently the company’s common shares owned by public are about 68.37M shares, out of which, 38.63M shares are available for trading.
Stock saw a price change of 41.01% in past 5 days and over the past one month there was a price change of 63.33%. Year-to-date (YTD), ZURA shares are showing a performance of -46.88% which decreased to -21.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.97 but also hit the highest price of $5.07 during that period. The average intraday trading volume for Zura Bio Ltd shares is 566.81K. The stock is currently trading 60.00% above its 20-day simple moving average (SMA20), while that difference is up 66.56% for SMA50 and it goes to -6.74% lower than SMA200.
Zura Bio Ltd (NASDAQ: ZURA) currently have 68.37M outstanding shares and institutions hold larger chunk of about 60.97% of that.
The stock has a current market capitalization of $121.27M and its 3Y-monthly beta is at -0.10. It has posted earnings per share of -$0.76 in the same period. It has Quick Ratio of 8.14 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ZURA, volatility over the week remained 15.01% while standing at 10.10% over the month.
Analysts are in expectations that Zura Bio Ltd (ZURA) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to drop by -25.83% while it is estimated to decrease by -5.52% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on November 04, 2024 offering an Outperform rating for the stock and assigned a target price of $15 to it. Coverage by H.C. Wainwright stated Zura Bio Ltd (ZURA) stock as a Neutral in their note to investors on September 05, 2024, suggesting a price target of $5 for the stock. On May 03, 2024, Piper Sandler Initiated their recommendations, while on October 10, 2023, Ladenburg Thalmann Initiated their ratings for the stock with a price target of $10. Stock get an Outperform rating from Oppenheimer on August 25, 2023.
